Clinical Trial

A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, dose-escalation, prospective exploratory clinical study intended to evaluate the safety, efficacy and cellular pharmacokinetics of GT737 cells in adult patients with relapsed/refractory acute myeloid leukemia (AML).
Trial Details
NCT Number NCT07676006
Lead Sponsor Grit Biotechnology
Collaborators: Shenzhen People's Hospital
Conditions Relapsed/Refractory Acute Myeloid Leukemia (AML)
Enrollment 36 participants
Start Date 2026-07-01
Primary Completion 2030-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-30